Pharma R&D changes spell trouble for Global South

Pharma R&D changes spell trouble for Global South

In 2023, Johnson & Johnson announced it had stopped research and development on therapeutics for many infectious diseases, including hepatitis and tuberculosis. Less visibly, AbbVie shuttered last year its pro bono technical R&D support on infectious diseases such as malaria and Chagas’ disease. These are not isolated cases. An increasing number of large pharmaceutical companies…

Read More
Ex-FDA regulator Peter Marks joins Eli Lilly

Ex-FDA regulator Peter Marks joins Eli Lilly

WASHINGTON — Peter Marks, the former top vaccine regulator at the Food and Drug Administration, has joined Eli Lilly to oversee molecule discovery and infectious diseases — a move likely to rile up critics of the revolving door between FDA and industry.  Marks confirmed his new role at Lilly Research Laboratories to STAT. His first day was…

Read More
Trump questions vaccine safety, urges changes to timing

Trump questions vaccine safety, urges changes to timing

WASHINGTON — President Trump on Monday suggested an overhaul to how children get vaccinated after claiming, without evidence, that many vaccines are unsafe as currently given. The president said he has talked with health secretary Robert F. Kennedy Jr. about his proposed changes. While Trump has occasionally expressed skepticism of some vaccines, the president’s comments…

Read More